Sujal Shah
2017
In 2017, Sujal Shah earned a total compensation of $5M as President and Chief Executive Officer at Cymabay Therapeutics.
Compensation breakdown
| Bonus | $272,294 |
|---|---|
| Option Awards | $4,359,595 |
| Salary | $393,207 |
| Other | $15,686 |
| Total | $5,040,782 |
Shah received $4.4M in option awards, accounting for 86% of the total pay in 2017.
Shah also received $272.3K in bonus, $393.2K in salary and $15.7K in other compensation.
Rankings
In 2017, Sujal Shah's compensation ranked 1,870th out of 14,666 executives tracked by ExecPay. In other words, Shah earned more than 87.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,870 out of 14,666 | 87th |
Division Manufacturing | 626 out of 5,772 | 89th |
Major group Chemicals And Allied Products | 166 out of 2,075 | 92nd |
Industry group Drugs | 121 out of 1,731 | 93rd |
Industry Pharmaceutical Preparations | 92 out of 1,333 | 93rd |
Source: SEC filing on April 20, 2018.
Shah's colleagues
We found three more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2017.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019